ORGS (Orgenesis) Ending Cash Position: $0.69 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORGS Orgenesis Inc ORGS
12 GF Score
Price $0.10
View Full Analysis

What is Orgenesis Ending Cash Position?

Orgenesis ORGS 12 Ending Cash Position is $0.69 Mil as of Dec. 2024. GuruFocus rates ORGS with a GF Score™ of 12/100.

Orgenesis's Ending Cash Position for the quarter that ended in Dec. 2024 was $0.69 Mil.

Orgenesis's quarterly Ending Cash Position declined from Jun. 2024 ($1.16 Mil) to Sep. 2024 ($1.12 Mil) and declined from Sep. 2024 ($1.12 Mil) to Dec. 2024 ($0.69 Mil).

Orgenesis's annual Ending Cash Position declined from Dec. 2022 ($6.37 Mil) to Dec. 2023 ($1.48 Mil) and declined from Dec. 2023 ($1.48 Mil) to Dec. 2024 ($0.69 Mil).

Orgenesis Ending Cash Position Related Terms

Orgenesis Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Orgenesis's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis Ending Cash Position Chart

Orgenesis Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.57 5.97 6.37 1.48 0.69

Orgenesis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.48 0.57 1.16 1.12 0.69
ORGS
12GF Score
Orgenesis Inc ORGS
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orgenesis Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Orgenesis's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1.479+-0.792
=0.69

Orgenesis's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1.122+-0.435
=0.69

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.69 Mil mean?
Orgenesis (ORGS) has a Ending Cash Position of $0.69 Mil as of Dec. 2024. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Orgenesis and its competitors.
Is Orgenesis' Ending Cash Position too high?
Orgenesis' current Ending Cash Position is $0.69 Mil. Overall, Orgenesis has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Orgenesis' Ending Cash Position compare to ENDV and GBLX?
Orgenesis' Ending Cash Position of $0.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Orgenesis and its competitors. Orgenesis's current Ending Cash Position is $0.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orgenesis stock overvalued right now?
Orgenesis (ORGS) has a current Ending Cash Position of $0.69 Mil. The current Ending Cash Position is $0.69 Mil. Orgenesis' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Orgenesis (ORGS), the current Ending Cash Position is $0.69 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Orgenesis Business Description

Address 20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies. The company's therapies pipeline includes Immuno-Oncology, Viral Diseases, Metabolic & Autoimmune Diseases, Vascular & Musculoskeletal Diseases, and Kidney Disease.
12GF Score

Get the complete analysis for ORGS

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price